NewcelX Bolsters Scientific Leadership with Neuroimmunology Expert, Signaling Promise for ALS & Diabetes Therapies

Zurich, Switzerland – November 6, 2025 – NewcelX Ltd. (NASDAQ: NCEL) is strengthening its scientific foundation with the addition of Professor Tamir Ben-Hur, a renowned expert in neuroimmunology and stem-cell-based regenerative medicine, to its Scientific Advisory Board. The appointment signals a strategic move by the biotech firm as it advances its pipeline of therapies targeting neurodegenerative and metabolic diseases, particularly Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes.

NewcelX was formed through the recent merger of Kadimastem Ltd. and NLS Pharmaceutic Ltd., combining cutting-edge stem-cell technologies with established expertise in central nervous system (CNS) therapeutics. The addition of Prof. Ben-Hur, a professor of Neurology at Hadassah Medical Center and the Hebrew University of Jerusalem, is widely viewed within the industry as a validation of this combined approach.

“This appointment is a pivotal moment for NewcelX,” said one industry analyst, speaking on background. “Prof. Ben-Hur’s deep understanding of neuroinflammation and his extensive experience in stem-cell research perfectly align with the company’s therapeutic focus. It sends a strong signal of intent to investors and, more importantly, offers hope to patients battling these devastating diseases.”

A Leader in Neuroimmunology Joins the Fold

Professor Ben-Hur’s research has focused extensively on the role of neuroinflammation in the progression of neurological disorders. His work has shed light on the complex interplay between the immune system and the brain, paving the way for novel therapeutic strategies. He is a prolific author with over 200 peer-reviewed publications in leading scientific journals, including Nature and The Lancet Neurology.

“The company clearly recognized the value of bolstering its scientific expertise,” said another source close to the company. “Prof. Ben-Hur isn’t just a name; he’s a thought leader. He will be instrumental in guiding the company’s research and development efforts, particularly in areas like modulating the immune response and optimizing stem-cell delivery.”

The Strategic Rationale Behind the Merger & Appointment

The merger of Kadimastem and NLS Pharmaceutic was predicated on the belief that combining their respective strengths would accelerate the development of innovative therapies for challenging diseases. Kadimastem brought to the table its proprietary stem-cell platform, while NLS Pharmaceutic possessed established expertise in CNS drug development and delivery. The addition of Prof. Ben-Hur serves as a catalyst, bringing a critical layer of scientific leadership to this already potent combination.

Analysts suggest that the move is particularly strategic in the context of the growing understanding of neuroinflammation’s role in ALS. “For years, ALS research focused primarily on motor neuron degeneration,” explained one biomedical researcher. “However, mounting evidence suggests that neuroinflammation plays a significant role in the disease process. Therapies that can effectively modulate the immune response and protect motor neurons are likely to be crucial for achieving meaningful clinical outcomes.”

ALS & Type 1 Diabetes: Unmet Medical Needs

Both ALS and Type 1 Diabetes represent significant unmet medical needs. ALS is a progressive neurodegenerative disease that affects motor neurons, leading to muscle weakness, paralysis, and ultimately, death. There is currently no cure for ALS, and existing treatments offer only modest benefits in slowing disease progression. Type 1 Diabetes, an autoimmune disease that destroys insulin-producing cells in the pancreas, requires lifelong insulin therapy and carries a significant risk of long-term complications.

NewcelX’s pipeline focuses on developing both cell-based and small-molecule therapies for these diseases. The company is exploring the potential of using stem cells to replace damaged motor neurons in ALS and to regenerate insulin-producing cells in Type 1 Diabetes. The company is also developing small-molecule drugs that can modulate the immune response and protect cells from damage.

“The potential here is enormous,” said a patient advocate involved in ALS research. “These diseases are incredibly challenging to treat, but NewcelX’s approach – combining stem cells with targeted therapies – offers a glimmer of hope for patients and families who have been desperately seeking new options.”

Competitive Landscape & Future Outlook

The biotechnology landscape for both ALS and Type 1 Diabetes is fiercely competitive. Companies like Biogen, Novartis, and Vertex Pharmaceuticals are actively pursuing therapies for ALS, while Sanofi, Eli Lilly, and Novo Nordisk are leading the charge in Type 1 Diabetes research. NewcelX will need to differentiate itself through innovation and clinical success to gain a foothold in these markets.

“NewcelX’s unique approach, combined with the expertise of Prof. Ben-Hur, could give them a significant competitive advantage,” said one investment analyst. “The company is well-positioned to capitalize on the growing demand for innovative therapies for these devastating diseases. However, they will need to demonstrate strong clinical results to attract further investment and secure regulatory approval.”

The appointment of Prof. Ben-Hur represents a significant step forward for NewcelX, signaling the company’s commitment to developing groundbreaking therapies for ALS and Type 1 Diabetes. While challenges remain, the company is poised to make a meaningful impact on the lives of patients battling these debilitating diseases. The company expects to announce initial clinical trial results within the next 18-24 months, which will be a crucial test of its technology and strategy.